论文部分内容阅读
目的:探讨参松养心胶囊对冠心病室性期前收缩的临床疗效和安全性。方法:对符合纳入标准的206例门诊或住院患者,采用随机双盲双模拟对照,按1:1随机分为治疗组103例,给予参松养心胶囊(4粒,3次/d),对照组103例给予心律宁片(2片,3次/d)。4周后进行室性期前收缩、主要症状、心电图等疗效及毒副作用的评估。结果:治疗组室性期前收缩显效率35.0%(36/103),总有效率69.0%(71/103),明显优于对照组显效率18.4%(19/103)与总有效率48.5%(50/103)(Z=-3.261,P=0.001)。结论:参松养心胶囊治疗冠心病室性期早搏明显优于心律宁片,未见对血、尿、便常规,肝、肾功能等的不良影响。
Objective: To investigate the clinical efficacy and safety of Shensong Yangxin Capsule on premature ventricular contraction in patients with coronary heart disease. Methods: A total of 206 outpatients or inpatients who met the inclusion criteria were randomly divided into treatment group (n = 103) treated with Shensong Yangxin Capsule (4 capsules, 3 times / d) Control group of 103 cases given heart rnning tablets (2 tablets, 3 times / d). 4 weeks after the ventricular contraction, the main symptoms, ECG and other side effects and evaluation. Results: The preoperative ventricular systolic effective rate was 35.0% (36/103), the total effective rate was 69.0% (71/103), significantly higher than that of the control group (18.4%, 19/103) and the total effective rate was 48.5% (50/103) (Z = -3.261, P = 0.001). Conclusion: Shensongyangxin Capsule is superior to Xinlining Tablet in treating ventricular premature beats of coronary heart disease, and no adverse effects on blood, urine, routine, liver and kidney function were found.